Strasbourg Cedex

• Phase 2 Study of REGN13335 in Adult Participants with Pulmonary Arterial Hypertension (PAH) Recruiting
  2024-514754-79-00 4 2026-05-06 Pulmonary Arterial Hypertension (PAH)
• A clinical study to test how safe and effective a new inhaled treatment (called L606) is for people with high blood pressure in the lungs du … Recruiting
  2024-517943-29-00 5 2026-04-21 Pulmonary Hypertension associated with interstitial lung disease (WHO
• A study to test the safety and disease progression following YTB323 (rapcabtagene autoleucel) administration in participant with progressive … Recruiting
  2024-514006-31-00 9 2026-04-16 Non-active Progressive Multiple Sclerosis (PMS)
• A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation Recruiting
  2025-521521-33-00 10 2026-04-02 Kidney transplant rejection
• A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy Recruiting
  2024-515635-30-00 3 2026-03-24 Coagulopathy
• A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product Recruiting
  2024-520222-11-00 3 2026-03-03 Hematological or solid tumor malignancies or autoimmune diseases
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini … Recruiting
  2025-521558-40-00 5 2026-02-12 Pulmonary Hypertension Associated with Interstitial Lung Disease
• An open-label study to assess the safety, efficacy, and cellular kinetics of YTB323 (rapcabtagene autoleucel) in Relapsingin Relapsing Multi … Recruiting
  2024-512714-18-00 9 2025-11-11 Relapsing Multiple Sclerosis
• AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri … Recruiting
  2024-516525-31-01 5 2025-07-14 Primary Biliary Cholangitis
• A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the … Recruiting
  2024-511239-91-00 4 2025-05-05 Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
• A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-li … Recruiting
  2024-518224-74-01 4 2025-02-07 metastatic non-small-cell lung cancer
• Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial Recruiting
  2024-514799-42-00 4 2024-11-05 IDIOPATHIC PULMONARY FIBROSIS
• CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al … Recruiting
  2024-517004-11-00 5 2024-10-22 Chronic pulmonary aspergillosis
• A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime … Recruiting
  2023-509807-34-00 4 2024-08-12 Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementi
• A study of different investigational treatments in people with the interstitial lung disease that accompanies scleroderma (CONQUEST) Recruiting
  2023-507129-40-00 4 2024-08-06 interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
• BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c … Recruiting
  2023-504308-27-00 5 2024-06-06 non-squamous non-small cell lung cancer
• A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po … Recruiting
  2023-505604-32-00 5 2024-01-24 Non small cell lung cancer (NSCLC)
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 5 2023-11-16 Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis o
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 4 2023-10-17 Large cell neuroendocrine carcinoma
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly … Recruiting
  2022-500275-31-00 5 2023-06-20 Haemophilia A
• A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease Recruiting
  2022-500718-24-00 5 2023-06-09 IgG4-Related Disease
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections

Showing 25–48 of 291 trials